Although PARPis were initially approved only for cancer patients with underlying defects in DNA damage repair, Niraparib has been recently approved as first-line maintenance therapy for advanced ovarian cancer in adults who responded to platinum-based chemotherapy, regardless of BRCA1/2 status (15). This evidence concerns the gene BRCA1 and ovarian cancer.